Top Markets
#1 Official Trump Official Trump +33.51%
#2 Siacoin Siacoin +20.98%
#3 Melania Meme Melania Meme +19.05%
#4 EXOD EXOD +18.93%
#5 Wrapped STX (Velar) Wrapped STX (Velar) +18.64%
#6 MowCat MowCat +18.17%
#7 POL (ex-MATIC) POL (ex-MATIC) +17.47%
#8 Wrapped POL Wrapped POL +16.96%
#9 Islamic Coin Islamic Coin +16.11%
#10 Siren Siren +15.86%
Coin of the day
Official Trump Official Trump
Settings
Language
ENGLISH
Currency
USD
Theme
Abliva AB (publ) Abliva AB (publ)

Abliva AB (publ)

ABLI
Rank in Stocks #22998
Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000,... Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).
Share Price
$0.04959193
Last synced: 2025-03-17
Market Cap
$79.94M
Change (1 day)
13.49%
Change (1 year)
0.00%
Country
SE
Trade Abliva AB (publ) (ABLI)

Category

Healthcare
Revenue for Abliva AB (publ) (ABLI)
Revenue in Aug 2026 TTM: 0
According to Abliva AB (publ) latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Abliva AB (publ) from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH